Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021

Analysis of the APAC Cardiac Troponin Diagnostics Market, Forecast to 2021

Increasing Incidence Rates of Myocardial Infarction and Aging Population in APAC Drive the Troponin Diagnostics Market

RELEASE DATE
16-Apr-2018
REGION
Asia Pacific
Research Code: P9F1-01-00-00-00
SKU: HC02980-AP-MR_21662

$3,000.00

Special Price $2,250.00 save 25 %

In stock
SKU
HC02980-AP-MR_21662

$3,000.00

$2,250.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility. Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US.

There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI.

Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and investments for the diagnosis of MI.

Key Issues Addressed

  • What are the key healthcare trends that could impact the APAC cardiac biomarker diagnostics market?
  • What are the market drivers and restraints that are impacting the market growth?
  • What are the unmet needs and the opportunities for the existing and emerging participants?
  • What are the segment shares of the key market participants?
  • How are companies dealing with the challenges in the market space?
  • What are the future trends and the forecast scenario of the AMI biomarkers diagnostics in a different region?

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Key Findings

Key Findings (Continued)

Scope and Segmentation

Key Questions This Study Will Answer

Market Engineering Measurements

Key Companies to Watch

Market Background

Cardiac Diagnostics Market Overview

Cardiac Biomarker Diagnostics Overview

Cardiac Diagnostics Overview

Market Overview—Testing Procedure

Defining Healthcare Trends in the Future

New Market Opportunities

Competitive Structures

Notable Deals and Launches—Cardiac Biomarker Diagnostics

Market Drivers

Drivers Explained

Drivers Explained (continued)

Market Restraints

Restraints Explained

Restraints Explained (continued)

Forecast Methodology

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Percent Revenue Forecast Breakdown by Segments

Market Share

Market Share Analysis

Major Growth Opportunities

Growth Opportunity Matrix

Growth Opportunity 1—Companion Diagnostics

Growth Opportunity 2—POCT in Cardiac Biomarker Diagnostics

Growth Opportunity 3—Integrated and Efficient System

Growth Opportunity 4—Digital Health and Diagnostics Inter-convergence Model

Strategic Imperative for Cardiac Troponins Market

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Segment Share

Segment Share Analysis

Market Engineering Measurements

Revenue Forecast

Revenue Forecast Discussion

Segment Share

Segment Share Analysis

The Last Word—3 Big Predictions

Legal Disclaimer

List of Exhibits

List of Exhibits (continued)

List of Others Companies

Market Engineering Methodology

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
Cardiac troponins will continue to remain the gold standard for early diagnosis of acute myocardial infarction (AMI); however, the key challenge to address is the advent of a complementary biomarker to prevent repeat diagnosis. Multiplexing platforms should be harnessed for simultaneous testing of complementary biomarkers such as H-FABP, cardiac myosin binding C protein, co-peptin, and Pentraxin 3 (PTX3) that should be combined with utmost clinical utility. Chinese Food & Drug Administration (CFDA) and regional market access to APAC countries such as Indonesia and India will emerge as key markets with early commercial access with the new proposed CE regulatory guidelines that require lengthy approval times and clinical benefits. Furthermore, with the huge market opportunities in emerging APAC countries, unlike the conventional approach APAC market, access will take a center stage in parallel with Europe and the US. There is a general trend toward decentralization of laboratory testing in hospitals that have demonstrated an overall improvement in operational efficiency by 30% to 40%, further supported by the overall trends in pathology price cuts as an indirect measure to rising healthcare expenditure. Given the overall market trends in central lab testing, there will be a higher propensity toward adoption of POCT, with quantitative outcomes for mainstream clinical diagnosis. There will be an increase in adoption of POCT, which would eventually shrink the lab-based market for troponin biomarkers used for the diagnosis of MI. Physicians are demanding for a more accurate test which could reduce the burden in the healthcare settings. For patients under the acute critical conditions such as myocardial infarction, fast results and quick diagnosis are required. The rising prevalence of MI and increasing morbidity in the region will fuel the growth of diagnostic testings. Moreover, demands from physicians for more accurate and sensitive results will push researchers and
More Information
No Index No
Podcast No
Author Nitin Naik
Industries Healthcare
WIP Number P9F1-01-00-00-00
Keyword 1 Cardiac Troponin
Is Prebook No
GPS Codes 9600-B1,9611-B1,9627-B1,99C1-B1,99C6-B1,9A43-B1,9A4E-B1,9A50-B1